COVID-19: an unexpected indication for anti-rheumatic therapies?

Lucchino, Bruno; Di Franco, Manuela; Conti, Fabrizio

Lucchino, Bruno; Di Franco, Manuela; Conti, Fabrizio.

Lucchino B; Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Di Franco M; Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Conti F; Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

Rheumatology (Oxford) ; 59(6): 1200-1203, 2020 06 01.

Article in English | MEDLINE | ID: covidwho-186601

Subject(s)

Antirheumatic Agents/therapeutic use; Coronavirus Infections/drug therapy; Pneumonia, Viral/drug therapy; Adalimumab/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Azetidines/therapeutic use; Betacoronavirus; COVID-19; Chloroquine/therapeutic use; Clinical Trials as Topic; Cytokine Release Syndrome/virology; Drug Repositioning; Humans; Hydroxychloroquine/therapeutic use; Pandemics; Purines; Pyrazoles; SARS-CoV-2; Sulfonamides/therapeutic use; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antirheumatic Agents Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Rheumatology (Oxford) Journal subject: Rheumatology Year: 2020 Document Type: Article Affiliation country: Rheumatology

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google